GlassScriptPhysician profile
Sally A Johnson
NPI 1518588243
$1,124.53
in general payments reported to CMS, 2019-2025
31 companies · $54.48 in 2025
The $54.48 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $455 · 2024: $616 · 2025: $54.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.58 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $119.81 | 2023-2024 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $62.03 | 2024 | |
| Lilly USA, LLC | $60.60 | 2024 | Verzenio, Jaypirca, Retevmo |
| Pharmacosmos Therapeutics INC. | $54.02 | 2023-2024 | Monoferric, Cosela |
| Eisai INC. | $53.57 | 2023 | |
| Agios Pharmaceuticals, INC. | $51.79 | 2023 | Pyrukynd |
| Merck Sharp & Dohme LLC | $51.27 | 2024 | Keytruda, Lynparza |
| Array Biopharma INC | $47.91 | 2024 | Xtandi, Inlyta, Talzenna |
| Astrazeneca Pharmaceuticals LP | $46.42 | 2024 | Tagrisso |
| Dendreon Pharmaceuticals LLC | $40.23 | 2024 | Provenge |
| Astellas Pharma US INC | $39.59 | 2023 | Xospata |
| Mirati Therapeutics, INC. | $37.96 | 2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $35.73 | 2023-2025 | |
| Blueprint Medicines Corporation | $32.61 | 2024 | Ayvakit |
| Incyte Corporation | $31.49 | 2024 | Jakafi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $30.89 | 2024 | Panzyga |
| Puma Biotechnology, INC. | $30.81 | 2024 | |
| Janssen Biotech, INC. | $30.43 | 2023-2024 | Tecvayli, Darzalex, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $30.01 | 2024 | Ninlaro |
| Apellis Pharmaceuticals, INC. | $25.32 | 2024 | Empaveli |
| Daiichi Sankyo INC. | $24.96 | 2024 | Enhertu |
| Aveo Pharmaceuticals, INC. | $23.53 | 2025 | |
| Amgen INC. | $22.95 | 2023 | Lumakras |
| Genzyme Corporation | $22.28 | 2023 | |
| Alexion Pharmaceuticals, INC. | $20.06 | 2023 | Ultomiris |
| Glaxosmithkline, LLC. | $18.69 | 2023 | Ojjaara |
| Sobi, INC | $18.25 | 2024 | |
| Emd Serono, INC. | $16.79 | 2023 | Bavencio |
| Genmab U.S., INC. | $15.79 | 2023 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $14.77 | 2023 | Opdivo |
| Abbvie INC. | $13.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.